Titre : Atrophie parodontale

Atrophie parodontale : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Hyperplasia
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Atrophie parodontale : Questions médicales les plus fréquentes", "headline": "Atrophie parodontale : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Atrophie parodontale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-09", "dateModified": "2025-04-04", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Atrophie parodontale" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Maladies parodontales", "url": "https://questionsmedicales.fr/mesh/D010510", "about": { "@type": "MedicalCondition", "name": "Maladies parodontales", "code": { "@type": "MedicalCode", "code": "D010510", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C07.465.714" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Résorption alvéolaire", "alternateName": "Alveolar Bone Loss", "url": "https://questionsmedicales.fr/mesh/D016301", "about": { "@type": "MedicalCondition", "name": "Résorption alvéolaire", "code": { "@type": "MedicalCode", "code": "D016301", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C07.465.714.354.500" } } }, { "@type": "MedicalWebPage", "name": "Récession gingivale", "alternateName": "Gingival Recession", "url": "https://questionsmedicales.fr/mesh/D005889", "about": { "@type": "MedicalCondition", "name": "Récession gingivale", "code": { "@type": "MedicalCode", "code": "D005889", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C07.465.714.354.625" } } }, { "@type": "MedicalWebPage", "name": "Perte d'attache parodontale", "alternateName": "Periodontal Attachment Loss", "url": "https://questionsmedicales.fr/mesh/D017622", "about": { "@type": "MedicalCondition", "name": "Perte d'attache parodontale", "code": { "@type": "MedicalCode", "code": "D017622", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C07.465.714.354.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Atrophie parodontale", "alternateName": "Periodontal Atrophy", "code": { "@type": "MedicalCode", "code": "D055093", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Frederik Barkhof", "url": "https://questionsmedicales.fr/author/Frederik%20Barkhof", "affiliation": { "@type": "Organization", "name": "From the Department of Neurology and Alzheimer Center (C.G., Y.A.L.P., P.S., W.M.v.d.F., R.O.), and Departments of Radiology and Nuclear Medicine (F.B.) and Epidemiology and Biostatistics (W.M.v.d.F.), Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands; Department of Electrical and Computer Engineering (B.T.T.Y., X.Z., N.S.), Clinical Imaging Research Centre, N1 Institute for Health and Memory Networks Program, National University of Singapore; Montreal Neurological Institute (J.W.V.), McGill University, Montreal, Canada; Computer Science and Artificial Intelligence Laboratory (X.Z.), Massachusetts Institute of Technology, Cambridge; Department of Neurology and Neurological Sciences (E.C.M.), Stanford University, CA; Departments of Neurology, Radiology and Biomedical Imaging (B.L.M., H.J.R., R.L.J., G.D.R.), University of California, San Francisco; Institutes of Neurology & Healthcare Engineering (F.B.), University College London, UK; and Clinical Memory Research Unit (R.O.), Lund University, Sweden." } }, { "@type": "Person", "name": "Maria Teresa Pellecchia", "url": "https://questionsmedicales.fr/author/Maria%20Teresa%20Pellecchia", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Surgery and Dentistry \"Scuola Medica Salernitana\", Neuroscience Section, University of Salerno, Baronissi, SA, Italy." } }, { "@type": "Person", "name": "Iva Stankovic", "url": "https://questionsmedicales.fr/author/Iva%20Stankovic", "affiliation": { "@type": "Organization", "name": "Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia." } }, { "@type": "Person", "name": "Gregor K Wenning", "url": "https://questionsmedicales.fr/author/Gregor%20K%20Wenning", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria." } }, { "@type": "Person", "name": "Klaus Seppi", "url": "https://questionsmedicales.fr/author/Klaus%20Seppi", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Frailty and benign prostatic hyperplasia: The thrilling underlying impact.", "datePublished": "2022-09-27", "url": "https://questionsmedicales.fr/article/36165483", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4081/aiua.2022.3.345" } }, { "@type": "ScholarlyArticle", "name": "Population pharmacokinetics of tamsulosine in patients with benign prostatic hyperplasia.", "datePublished": "2024-07-22", "url": "https://questionsmedicales.fr/article/39037497", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00345-024-05115-w" } }, { "@type": "ScholarlyArticle", "name": "Characterization of the histological response to the Butterfly Prostatic Retraction Device in patients with benign prostatic hyperplasia.", "datePublished": "2023-02-17", "url": "https://questionsmedicales.fr/article/36797501", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00345-023-04319-w" } }, { "@type": "ScholarlyArticle", "name": "Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia.", "datePublished": "2022-10-05", "url": "https://questionsmedicales.fr/article/36198834", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00432-022-04380-9" } }, { "@type": "ScholarlyArticle", "name": "The Effect of Transurethral Resection of the Prostate on Erectile and Ejaculatory Functions in Patients with Benign Prostatic Hyperplasia.", "datePublished": "2022-06-02", "url": "https://questionsmedicales.fr/article/35654017", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000524957" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système stomatognathique", "item": "https://questionsmedicales.fr/mesh/D009057" }, { "@type": "ListItem", "position": 3, "name": "Maladies de la bouche", "item": "https://questionsmedicales.fr/mesh/D009059" }, { "@type": "ListItem", "position": 4, "name": "Maladies parodontales", "item": "https://questionsmedicales.fr/mesh/D010510" }, { "@type": "ListItem", "position": 5, "name": "Atrophie parodontale", "item": "https://questionsmedicales.fr/mesh/D055093" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Atrophie parodontale - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Atrophie parodontale", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-30", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Atrophie parodontale", "description": "Comment diagnostiquer l'atrophie parodontale ?\nQuels tests sont utilisés pour évaluer l'atrophie ?\nQuels signes cliniques indiquent l'atrophie ?\nL'atrophie parodontale est-elle réversible ?\nQuel rôle joue l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D055093?mesh_terms=Prostatic+Hyperplasia&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Atrophie parodontale", "description": "Quels sont les symptômes de l'atrophie parodontale ?\nL'atrophie parodontale cause-t-elle des douleurs ?\nPeut-on avoir des gencives qui saignent ?\nComment l'atrophie affecte-t-elle l'apparence des dents ?\nY a-t-il un lien entre l'atrophie et la sensibilité dentaire ?", "url": "https://questionsmedicales.fr/mesh/D055093?mesh_terms=Prostatic+Hyperplasia&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Atrophie parodontale", "description": "Comment prévenir l'atrophie parodontale ?\nQuel rôle joue le brossage des dents ?\nLes produits de rinçage buccal sont-ils utiles ?\nL'alimentation influence-t-elle la santé parodontale ?\nFumer affecte-t-il la santé parodontale ?", "url": "https://questionsmedicales.fr/mesh/D055093?mesh_terms=Prostatic+Hyperplasia&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Atrophie parodontale", "description": "Quels traitements sont disponibles pour l'atrophie parodontale ?\nLa chirurgie est-elle nécessaire pour traiter l'atrophie ?\nLes antibiotiques sont-ils utilisés dans le traitement ?\nComment la thérapie au laser aide-t-elle ?\nLes traitements sont-ils douloureux ?", "url": "https://questionsmedicales.fr/mesh/D055093?mesh_terms=Prostatic+Hyperplasia&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Atrophie parodontale", "description": "Quelles complications peuvent survenir avec l'atrophie ?\nL'atrophie parodontale peut-elle affecter la santé générale ?\nY a-t-il un risque accru de diabète ?\nComment l'atrophie affecte-t-elle la qualité de vie ?\nLes infections parodontales peuvent-elles se propager ?", "url": "https://questionsmedicales.fr/mesh/D055093?mesh_terms=Prostatic+Hyperplasia&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Atrophie parodontale", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque d'atrophie ?\nLe stress a-t-il un impact sur la santé parodontale ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nUne alimentation déséquilibrée influence-t-elle le risque ?", "url": "https://questionsmedicales.fr/mesh/D055093?mesh_terms=Prostatic+Hyperplasia&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'atrophie parodontale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par un examen clinique et des radiographies dentaires." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'atrophie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des sondages parodontal et des radiographies sont utilisés pour évaluer la perte osseuse." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent l'atrophie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent la récession gingivale et la mobilité dentaire." } }, { "@type": "Question", "name": "L'atrophie parodontale est-elle réversible ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'atrophie parodontale est généralement irréversible, mais peut être stabilisée." } }, { "@type": "Question", "name": "Quel rôle joue l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique médical aide à identifier les facteurs de risque et les antécédents de maladies." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'atrophie parodontale ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des gencives enflammées, des douleurs et une mauvaise haleine." } }, { "@type": "Question", "name": "L'atrophie parodontale cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des douleurs lors de la mastication ou de la pression sur les dents." } }, { "@type": "Question", "name": "Peut-on avoir des gencives qui saignent ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les gencives peuvent saigner lors du brossage ou de l'utilisation de fil dentaire." } }, { "@type": "Question", "name": "Comment l'atrophie affecte-t-elle l'apparence des dents ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner un aspect plus long des dents en raison de la récession gingivale." } }, { "@type": "Question", "name": "Y a-t-il un lien entre l'atrophie et la sensibilité dentaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'atrophie peut augmenter la sensibilité dentaire aux aliments chauds ou froids." } }, { "@type": "Question", "name": "Comment prévenir l'atrophie parodontale ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hygiène bucco-dentaire et des visites régulières chez le dentiste sont essentielles." } }, { "@type": "Question", "name": "Quel rôle joue le brossage des dents ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le brossage régulier aide à éliminer la plaque dentaire et à prévenir les maladies parodontales." } }, { "@type": "Question", "name": "Les produits de rinçage buccal sont-ils utiles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains rince-bouche antibactériens peuvent aider à réduire l'inflammation gingivale." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la santé parodontale ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée riche en vitamines et minéraux favorise la santé des gencives." } }, { "@type": "Question", "name": "Fumer affecte-t-il la santé parodontale ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque de maladies parodontales et d'atrophie." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour l'atrophie parodontale ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent le détartrage, le surfaçage radiculaire et la chirurgie parodontale." } }, { "@type": "Question", "name": "La chirurgie est-elle nécessaire pour traiter l'atrophie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie peut être nécessaire dans les cas avancés pour restaurer le tissu parodontal." } }, { "@type": "Question", "name": "Les antibiotiques sont-ils utilisés dans le traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antibiotiques peuvent être prescrits pour traiter les infections parodontales." } }, { "@type": "Question", "name": "Comment la thérapie au laser aide-t-elle ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie au laser peut réduire l'inflammation et favoriser la guérison des tissus parodontal." } }, { "@type": "Question", "name": "Les traitements sont-ils douloureux ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent causer un certain inconfort, mais des anesthésiques sont utilisés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'atrophie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la perte de dents, des infections et des problèmes de mastication." } }, { "@type": "Question", "name": "L'atrophie parodontale peut-elle affecter la santé générale ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent un lien entre les maladies parodontales et des problèmes systémiques." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de diabète ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies parodontales peuvent aggraver le contrôle glycémique chez les diabétiques." } }, { "@type": "Question", "name": "Comment l'atrophie affecte-t-elle la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner des douleurs, des difficultés à manger et une baisse de l'estime de soi." } }, { "@type": "Question", "name": "Les infections parodontales peuvent-elles se propager ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections peuvent se propager à d'autres parties du corps, augmentant les risques." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux facteurs incluent le tabagisme, le diabète, et une mauvaise hygiène bucco-dentaire." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'atrophie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'atrophie parodontale augmente avec l'âge en raison de l'usure des tissus." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur la santé parodontale ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut affaiblir le système immunitaire et aggraver les maladies parodontales." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque d'atrophie parodontale." } }, { "@type": "Question", "name": "Une alimentation déséquilibrée influence-t-elle le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation pauvre en nutriments peut affaiblir les gencives et favoriser l'atrophie." } } ] } ] }

Sources (10000 au total)

Frailty and benign prostatic hyperplasia: The thrilling underlying impact.

World population is aging. The number of individuals aged over 65 are expected to be 71 million only in the US. 43% of this population will be men. Benign prostatic hyperplasia (BPH), defined as the b... The purpose of this study is to review the potential interplay between frailty syndrome and benign prostatic hyperplasia. A thorough MEDLINE/PubMed non-systematic literature review was conducted from ... It seems that, frailty poses a negative impact on the prognosis of patients with BPH, as it is associated with increased incidence of LUTS. In addition, frailty seems to be a strong predictor concerni... BPH has a strong association with frailty and increasing age....

Population pharmacokinetics of tamsulosine in patients with benign prostatic hyperplasia.

The study aimed to determine the typical clearance and volume of distribution values of tamsulosin in patients with benign prostatic hyperplasia (BPH), and to identify factors with a measurable impact... This open-label, single-arm population pharmacokinetic study involved 65 adult men with BPH who had been on tamsulosin therapy for at least seven days. The steady-state serum concentrations of tamsulo... The estimated tamsulosin clearance in BPH patients was 0.719 L/h, and the steady-state volume of distribution was 32 L. Neither renal nor liver function parameters had a statistically significant effe... Our investigation reveals significant associations between tamsulosin pharmacokinetics and specific characteristics of patients with lower urinary tract symptoms (LUTS) due to BPH. The study highlight...

Characterization of the histological response to the Butterfly Prostatic Retraction Device in patients with benign prostatic hyperplasia.

The Butterfly Prostatic Retraction Device ("Butterfly") is a permanent nitinol implant for benign prostatic hyperplasia. This study examines the chronic response of prostate tissue to the Butterfly in... Retrospective qualitative and semi-quantitative review of histological specimens of seven (7) patients who participated in the Butterfly pilot clinical study. Patients had at least 1-month implantatio... Four out of six patients had IPSS decreased from baseline. All seven patients' samples had signs of chronic inflammation; one demonstrated acute inflammation and one demonstrated fibrosis. In three ca... The Butterfly demonstrated an overall favorable safety profile in terms of tissue response. This study demonstrates that there is no significant tissue reaction in the prostatic urethra due to presenc...

Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia.

Markers are needed to increase the diagnostic accuracy of prostate-specific antigen (PSA) in prostate cancer (PCa) screening. Mounting evidence has shown that plasma proteins can be hopeful biomarkers... Tandem mass tag (TMT)-based proteomics and parallel reaction monitoring (PRM) analysis were used to screen the differential proteins and further validated in other independent studies (n = 539). Recei... Three candidate proteins (DBP, LCAT and ORM2) were preliminarily screened. Subsequent validation studies revealed significant upregulation of ORM2 in PCa patients across other independent cohorts. ORM... In summary, our study suggests that ORM2 could be treated as a complementary biomarker for PSA in distinguishing PCa from BPH....

The Effect of Transurethral Resection of the Prostate on Erectile and Ejaculatory Functions in Patients with Benign Prostatic Hyperplasia.

The aim of this study was to investigate the effect of TURP on erectile function (EF) and ejaculatory function (EJF).... A total of 91 patients who underwent TURP were retrospectively assessed. Patients were divided into two groups based on International Index of Erectile Function (IIEF-5): group A included 41 patients ... In group A, there were no significant statistical differences in mean IIEF-5 at baseline and after TURP 22.88 ± 0.81 versus 22.63 ± 2.63 (p = 0.065). However, in group B, there was significant improve... The results confirmed that TURP has no significant negative influence on EF, and patients with preexisting ED were improved after TURP. On the contrary, the loss of EJF was significant....

Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.

Diabetes has been associated with an increased risk of benign prostatic hyperplasia (BPH). However, the role of antidiabetic drugs as a BPH risk factor is unclear. The objective of our study was to ex... A total of 74,754 men in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) free of BPH at baseline in 1996-1999 were linked to the national medication reimbursement database for ... Of the subjects, 14,012 men (18.7%) used antidiabetic medication. Of the subgroup with fasting blood glucose data available, 7487 (42.2%) had diabetic level. The risks for BPH diagnosis (HR: 1.08, 95%... Diabetic BGL and antidiabetic medication use, especially insulin, are associated with an elevated risk of BPH surgery compared to nondiabetic men. These findings support the roles of insulin use and u...

Numerical investigation of urethra flow characteristics in benign prostatic hyperplasia.

Conventional practice includes a limited depiction of urethral pressure and flows based on fragmented gross clinical observations. However, with technological advancements in simulations, computationa... Three-dimensional urethra models were constructed for seven specific subjects based on clinical radiographs. Simulations with Reynolds averaged Navier-Stokes model were performed to quantitatively inv... Under benign prostatic hyperplasia, the spindle shape of the prostatic urethra (PRU) generates wake flow. The wake flow was also observed in several regions downstream of the PRU, depending on the ure... Numerical simulation can describe the urine flow field in the urethra, providing the possibility to predict the bladder pressure without requiring painful, invasive interventions, such as cystoscopy. ...

Racial Disparities in Diagnosis and Management of Benign Prostatic Hyperplasia: A Review.

We sought to perform a contemporary literature review highlighting the racial disparities which exists in the evaluation and management of benign prostatic hyperplasia (BPH).... Current literature suggests that racial disparities exist in the diagnosis of BPH and treatment lower urinary tract symptoms (LUTS). This is seen in the presentation and diagnosis of the disease as we...

Current Practice Patterns in the Surgical Management of Benign Prostatic Hyperplasia.

To use American Board of Urology (ABU) case log data to elucidate practice patterns for benign prostatic hyperplasia (BPH) surgery. Several surgical modalities have been introduced in recent decades c... We retrospectively analyzed ABU case logs from 2008-2021 to assess trends in BPH surgery. We created logistic regression models to identify surgeon-sided factors associated with utilization of each su... We identified 6,632 urologists who logged 73,884 surgeries for BPH. Transurethral resection of the prostate (TURP) was the most commonly performed BPH surgery in all but 1 year, and odds of performing... In the face of newer technologies, TURP remains the most common surgery for BPH in the United States. PUL has been rapidly adopted while HoLEP comprises a consistent minority of cases. Surgeon age, pa...